Literature DB >> 10570021

Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat.

K Matsui1, M Mishima, Y Nagai, T Yuzuriha, T Yoshimura.   

Abstract

Donepezil hydrochloride (Aricept) is a drug for the treatment of Alzheimer's disease. The absorption, distribution, metabolism, and excretion of donepezil were investigated in male Sprague-Dawley rats after a single oral administration. Orally administered (14)C-labeled donepezil was absorbed rapidly. The plasma level of unchanged donepezil declined more rapidly than that of radioactivity, and the brain level of radioactivity declined almost in parallel with the plasma level of unchanged donepezil. The ratio of donepezil to total radioactivity in brain was 86.9 to 93.0%, indicating low permeability of the metabolites through the blood-brain barrier. No heterogeneous localization of radioactivity was recognized in the brain and the concentration in each part of the brain was 1.74 to 2.24 times the plasma concentration. Cumulative biliary, urinary, and fecal excretion of radioactivity in bile duct-cannulated rats was 72.9, 24.4, and 8.84%, respectively, of the administered radioactivity at 48 h after administration. These results indicate that the absorption of donepezil is almost complete, and that its metabolites are mainly excreted into feces through the bile and some of them are subject to enterohepatic circulation. The metabolism of donepezil was extensive in rats and involved O-demethylation, aromatic hydroxylation, N-dealkylation, N-oxidation, and glucuronide conjugation of O-demethylate. The structures of the metabolites were determined by mass spectrometry and (1)H-NMR analysis. In plasma, urine, and bile, O-glucuronides accounted for the majority of the radioactivity, and in brain, unchanged donepezil was mostly detected. No metabolites were found in brain. There was no notable accumulation of radioactivity in whole blood and tissues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570021

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Alternative method of oral dosing for rats.

Authors:  Zeenat Atcha; Claire Rourke; Aveline Hp Neo; Catherine Wh Goh; Jean Sk Lim; Chiu-Cheong Aw; Edward R Browne; Darrel J Pemberton
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-05       Impact factor: 1.232

2.  Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil.

Authors:  Kristin Huse Haug; Inger Lise Bogen; Harald Osmundsen; Ivar Walaas; Frode Fonnum
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

Review 3.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

4.  Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.

Authors:  Anna Folkesson; Per Hartvig Honoré; Lene Munkholm Andersen; Pernille Kristensen; Ole J Bjerrum
Journal:  J Neural Transm (Vienna)       Date:  2010-10-02       Impact factor: 3.575

5.  Analysis of electropharmacological and proarrhythmic effects of donepezil using the halothane-anesthetized intact dogs and the conscious chronic atrioventricular block ones.

Authors:  Mihoko Hagiwara-Nagasawa; Ryuichi Kambayashi; Ai Goto; Yoshio Nunoi; Hiroko Izumi-Nakaseko; Koki Chiba; Takeshi Wada; Yoshinori Takei; Akio Matsumoto; Atsushi Sugiyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-16       Impact factor: 3.000

6.  A recursive-partitioning model for blood-brain barrier permeation.

Authors:  S R Mente; F Lombardo
Journal:  J Comput Aided Mol Des       Date:  2005-12-06       Impact factor: 3.686

7.  No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [123I]FP-CIT binding in rats.

Authors:  R J J Knol; K de Bruin; B L F van Eck-Smit; J Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-23       Impact factor: 9.236

Review 8.  Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.

Authors:  Muriel Noetzli; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

9.  Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats.

Authors:  Mireille Basselin; Henry N Nguyen; Lisa Chang; Jane M Bell; Stanley I Rapoport
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  On the inhibitory affect of some dementia drugs on DNA polymerase Beta activity.

Authors:  V N Vyjayanti; N S Chary; Kalluri Subba Rao
Journal:  Neurochem Res       Date:  2008-01-10       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.